IMMUNE-MEDIATED NECROTIZING MYOPATHY
Clinical trials for IMMUNE-MEDIATED NECROTIZING MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear
Sign up with your email to follow new studies for IMMUNE-MEDIATED NECROTIZING MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immun…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: NA • Sponsor: Shenzhen Genocury Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC